Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK. Rangwala R, et al. Among authors: amaravadi rk. Autophagy. 2014 Aug;10(8):1369-79. doi: 10.4161/auto.29118. Epub 2014 May 20. Autophagy. 2014. PMID: 24991839 Free PMC article. Clinical Trial.
The MAPK pathway in melanoma.
Fecher LA, Amaravadi RK, Flaherty KT. Fecher LA, et al. Among authors: amaravadi rk. Curr Opin Oncol. 2008 Mar;20(2):183-9. doi: 10.1097/CCO.0b013e3282f5271c. Curr Opin Oncol. 2008. PMID: 18300768 Review.
Drug targeting of oncogenic pathways in melanoma.
Fecher LA, Amaravadi RK, Schuchter LM, Flaherty KT. Fecher LA, et al. Among authors: amaravadi rk. Hematol Oncol Clin North Am. 2009 Jun;23(3):599-618, x. doi: 10.1016/j.hoc.2009.03.004. Hematol Oncol Clin North Am. 2009. PMID: 19464605 Review.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Sosman JA, et al. Among authors: amaravadi rk. N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302. N Engl J Med. 2012. PMID: 22356324 Free PMC article. Clinical Trial.
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.
McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, Lynch JP, Uehara T, Sepulveda AR, Davis LE, Winkler JD, Amaravadi RK. McAfee Q, et al. Among authors: amaravadi rk. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8253-8. doi: 10.1073/pnas.1118193109. Epub 2012 May 7. Proc Natl Acad Sci U S A. 2012. PMID: 22566612 Free PMC article.
Lys05: a new lysosomal autophagy inhibitor.
Amaravadi RK, Winkler JD. Amaravadi RK, et al. Autophagy. 2012 Sep;8(9):1383-4. doi: 10.4161/auto.20958. Epub 2012 Aug 10. Autophagy. 2012. PMID: 22878685 Free PMC article.
163 results